Intranasal Dexmedetomidine Is an Effective Sedative Agent for Electroencephalography in Children

Hang Chen; Fei Yang; Mao Ye; Hui Liu; Jing Zhang; Qin Tian; Ruiqi Liu; Qing Yu; Shangyingying Li; Shengfen Tu


BMC Anesthesiol. 2020;20(61) 

In This Article

Abstract and Introduction


Background: Intranasal dexmedetomidine (DEX), as a novel sedation method, has been used in many clinical examinations of infants and children. However, the safety and efficacy of this method for electroencephalography (EEG) in children is limited. In this study, we performed a large-scale clinical case analysis of patients who received this sedation method. The purpose of this study was to evaluate the safety and efficacy of intranasal DEX for sedation in children during EEG.

Methods: This was a retrospective study. The inclusion criteria were children who underwent EEG from October 2016 to October 2018 at the Children's Hospital affiliated with Chongqing Medical University. All the children received 2.5 μg·kg− 1 of intranasal DEX for sedation during the procedure. We used the Modified Observer Assessment of Alertness/Sedation Scale (MOAA/S) and the Modified Aldrete score (MAS) to evaluate the effects of the treatment on sedation and resuscitation. The sex, age, weight, American Society of Anesthesiologists physical status (ASAPS), vital signs, sedation onset and recovery times, sedation success rate, and adverse patient events were recorded.

Results: A total of 3475 cases were collected and analysed in this study. The success rate of the initial dose was 87.0% (3024/3475 cases), and the success rate of intranasal sedation rescue was 60.8% (274/451 cases). The median sedation onset time was 19 mins (IQR: 17–22 min), and the sedation recovery time was 41 mins (IQR: 36–47 min). The total incidence of adverse events was 0.95% (33/3475 cases), and no serious adverse events occurred.

Conclusions: Intranasal DEX (2.5 μg·kg− 1) can be safely and effectively used for EEG sedation in children.